Search PubMed⌕ Search

Biomedical subjects

J Benjamin

Publications and source records attributed to J Benjamin.

113 records · Page 7Linked to original sources

DSM-III and DSM-III-R schizotypal symptoms in borderline personality disorder.

The frequency of DSM-III and DSM-III-R schizotypal personality disorder (SPD) symptoms and diagnosis was explored in 39 inpatients classified as borderline by the Diagnostic Interview for Borderlines (DIB) and 19 inpatient major depressive disorder (MDD) controls. Most SPD symptoms in all groups, except the nondepressed borderlines, derived from social-interpersonal items. By DSM-III, 24 borderlines (62%) but only six controls (32%) had cognitive-perceptual SPD symptoms (P = .03), whereas by DSM-III-R only 14 borderlines (36%) and seven controls (37%) had such symptoms. Of the 24 borderlines showing cognitive-perceptual symptoms, 16 also had MDD, a significant difference from the non-MDD borderlines (P = .04). This difference disappears in DSM-III-R. The results suggest that some SPD symptoms in borderlines may be related to a concurrent affective episode.

Adult↗

A placebo-controlled cross-over trial of adjunctive EPA in OCD.

Several clinical studies showed beneficial effects of omega-3 fatty acids in major affective disorders, including resistant depression. Some antidepressants are also effective, albeit less so, in obsessive-compulsive disorder (OCD). We therefore undertook a preliminary placebo-controlled cross-over trial of adjunctive eicosapentaenoic acid (EPA) in OCD. Eleven patients with current obsessive-compulsive disorder, who were on a stable maximally tolerated dose of SSRI with no further improvement over at least the last two months, were recruited. Subjects were randomly allocated to begin 6 weeks of placebo (2 g liquid paraffin per day) followed by 6 weeks of 2 g of EPA or EPA followed by placebo. Patients continued their prior SSRIs at the same dose. Assessments were performed with the Yale-Brown Obsessive-Compulsive Scale (YBOCS), and the Hamilton Rating Scales for depression (HAM-D) and anxiety (HAM-A). There were no effects of order of treatment. Time had a main effect of YBOCS scores; mean scores declined from 26.0 (+/-5) to 17.6 (+/-6) by week 6 on placebo and to 18.5 (+/-4) on EPA. There were no effects on HAM-D and HAM-A. No clinically relevant side effects were reported. The results of this study suggest that adjunctive EPA is ineffective against OCD.

Administration, Oral↗

Acute inositol does not attenuate m-CPP-induced anxiety, mydriasis and endocrine effects in panic disorder.

Many anti-panic drugs, administered chronically, can block pharmacologically-induced "panic attacks"; acutely they often exacerbate panic disorder. Theories of action need to account for this biphasic effect. Chronic inositol had previously shown efficacy against panic disorder. The authors investigated the effect of a single dose of 20 g inositol on an m-CPP challenge in a double-blind placebo-controlled crossover trial in panic-disorder patients. Seven patients had robust psychological, physiological and endocrine responses to 0.08 mg m-CPP i.v.; inositol had virtually no effect on these responses, although it had some acute effects during the evening before the challenge. A similar trial involving chronic inositol would be of interest.

Anti-Anxiety Agents↗

Genes for human personality traits.

This article considers three major problems with the concept of genes for human personality traits: (1) uncertainty about what human personality is; (2) what we mean when we say there is a gene "for" a mental attribute; and (3) the complexity of interactions between genes and environment, and among the genes themselves. It then draws on examples from empirical human genetic studies by the author and his colleagues in order to suggest that the concept of genes for human personality traits nevertheless does have some validity, and also that we may be on the brink of discovering genes with major effects on human personality. This possibility, in particular its ethical aspects, has aroused some public concern. It is suggested that confidential information about an individual's genes does not differ in principle from other confidential information about him or her, and that the ability (currently theoretical) to affect genes and their expression, temporarily or permanently, does not differ ethically from our current ability to affect other aspects of an individual's physical and psychological functioning. Genes for potential offspring, contained in ova and sperm cells, constitute a special case.

Genes↗